Mesothelioma and Asbestos

BioDelivery Sciences International (BDSI) received a recent United States patent to provide additional patent exclusivity for the cancer pain drug Onsolis as well as the company’s BEMA drug delivery technology platform for at least the next 10 years. BDSI is planning to request a further extension on the patent protection until 2020.

Onsolis was recently approved by the Food as well as Drug Administration (FDA) for the treatment of breakthrough pain in adult cancer patients who are already receiving opioid therapy for their persistent cancer pain. Onsolis should be available for sale in the US in beginning fourth quarter of 2009.

For the filled story, go to Trading Markets.